COTUM 250MG TABLET
Out of Stock
Cotum 250mg Tablet, manufactured by Misae Lifesciences Pvt Ltd, is a prescription-only oral antibiotic tablet containing Cefuroxime Axetil 250mg, a second-generation, semi-synthetic cephalosporin antibiotic formulated to combat a broad range of susceptible bacterial infections affecting multiple organ systems. Bacterial infections in animals, just as in humans, can progress rapidly from localised discomfort to systemic illness when left untreated or when managed with antibiotics of insufficient spectrum. Cotum targets this challenge by delivering Cefuroxime, a bactericidal agent with reliable activity against both Gram-positive and Gram-negative organisms, in a convenient oral tablet format that offers systemic distribution following once or twice-daily dosing under veterinary direction. In veterinary practice, Cefuroxime Axetil is employed under professional supervision for the management of bacterial infections of the respiratory tract, urinary tract, skin and soft tissues, ears, and joints in dogs and cats. Animeal is proud to offer Cotum 250mg Tablet as part of our curated range of prescription pharmaceutical products available to support the health of your canine and feline companions under veterinary guidance.
Ingredients:
Cefuroxime Axetil IP (250mg per tablet): Cefuroxime Axetil (C20H22N4O10S) is an orally active prodrug ester of Cefuroxime, a second-generation cephalosporin antibiotic. As a prodrug, Cefuroxime Axetil itself is pharmacologically inactive. Upon oral administration, it is absorbed across the gastrointestinal mucosa and undergoes rapid hydrolysis by non-specific esterases in the intestinal epithelial cells and plasma, releasing the active moiety Cefuroxime into the systemic circulation. The oral bioavailability of Cefuroxime from Cefuroxime Axetil tablets is approximately 37% on an empty stomach and increases meaningfully to approximately 52% when the tablet is administered with food, making co-administration with a meal the preferred clinical approach. At the molecular level, Cefuroxime exerts its bactericidal action by binding to and irreversibly inhibiting penicillin-binding proteins (PBPs), a family of bacterial transmembrane enzymes, including transpeptidases and carboxypeptidases, that are essential for the final cross-linking steps of peptidoglycan biosynthesis in the bacterial cell wall. Inhibition of PBPs prevents the formation of a structurally sound cell wall, leading to the accumulation of unlinked peptidoglycan precursors, loss of cell wall integrity, osmotic instability, cell lysis, and bacterial death. Because Cefuroxime targets a biosynthetic pathway absent in mammalian cells, it exerts selective toxicity against bacteria while sparing host tissue. Cefuroxime is resistant to hydrolysis by a number of beta-lactamases commonly produced by Gram-negative organisms, which contributes to its broader spectrum of activity compared to first-generation cephalosporins. Its plasma elimination half-life is approximately 1.2 hours in healthy adults, with excretion primarily via renal tubular secretion and glomerular filtration. The antibacterial spectrum includes Staphylococcus aureus (methicillin-sensitive), Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Moraxella catarrhalis.
